Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that over $10 million of CSL Behring's Privigen was sold in the U.S. during the third quarter of 2008. Privigen is the newest brand of intravenous immune globulin (IVIG) and was launched in the first quarter of 2008. IVIG is a product created from the blood plasma of thousands of donors and is used to treat immune deficiencies, inflammatory and autoimmune diseases, acute infections and various other diseases.

The newly released edition of the IVIG Market Guide (U.S.) also finds that Baxter sold more grams of IVIG to hospitals than any other company in the U.S. during the third quarter of 2008. Baxter is currently the leader in hospital sales of IVIG.

"Based on recent news, if CSL Behring acquires Talecris, CSL Behring's market share of IVIG will increase significantly and could potentially surpass Baxter as the leader in hospital sales of IVIG," added Matthew W. Mahr, Pharm.D., M.B.A., analyst at AMR.

Why Pharmaceutical Companies Need this Information

The IVIG Market Guide (U.S.) enables pharmaceutical companies to monitor hospital utilization rates of intravenous immune globulin products. The data captured in this audit reveals usage by indication, dosing, ordering physician specialty and patient demographics for recipients of this group of products.

About The IVIG Market Guide (U.S.)

The IVIG Market Guide (U.S.) is the industry's most comprehensive market research study of IVIG. This product has two separate components including The IVIG Hospital Patient Profile Reports and The IVIG Hospital Purchasing Audit. The purchasing audit provides IVIG product market shares (in grams and dollars) and is produced twice a year. The patient profile report identifies relative usage patterns by indication, patient demographics, prescribing physician, dosing and insurance coverage and is produced once a year.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Natalia Morales               Elizabeth Marshall   Decision Resources            Decision Resources, Inc.   781-296-2691                  781-296-2563   nmorales@dresources.com       emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Arlington Medical Resources

CONTACT: Natalia Morales of Decision Resources, +1-781-296-2691,
nmorales@dresources.com; Elizabeth Marshall, Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

China's Major Depression Drug Market will Triple by 2012

View Now